Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RSDecon is a specialized brand within Emergent BioSolutions that focuses on providing advanced decontamination solutions for chemical and biological threats. The company's primary product is the Reactive Skin Decontamination Lotion (RSDL), a patented, broad-spectrum liquid decontaminant used to neutralize chemical warfare agents and biological toxins on the skin. RSDL is cleared by the FDA as a medical device and is utilized by military forces, first responders, and law enforcement agencies worldwide. It is effective against a variety of threats, including nerve agents like VX and Sarin, as well as blister agents like Sulfur Mustard. RSDecon plays a critical role in the global biodefense infrastructure by offering rapid-response medical countermeasures. The technology was originally developed by the Canadian Department of National Defence before being commercialized and eventually acquired by Emergent BioSolutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RS Decon.